Beam Therapeutics Receives U.S. FDA Orphan Drug Designation for BEAM-302 to Treat Alpha-1 Antitrypsin Deficiency
Friday, May 30, 2025
Beam Therapeutics Inc., a biotechnology firm focused on precision genetic medicines through base editing, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy BEAM-302. This treatment is being developed for Alpha-1 Antitrypsin Deficiency (AATD), a rare inherited disorder that can lead to serious lung and liver conditions.
BEAM-302 is a liver-targeted lipid-nanoparticle (LNP) formulation containing a guide RNA and mRNA encoding a base editor. It is designed to correct the PiZ mutation, which is the root cause of AATD in patients with the PiZZ genotype—the most severe form of the condition.
The orphan drug designation supports the development of treatments for rare diseases that affect fewer than 200,000 individuals in the U.S. It also offers potential benefits such as tax credits for clinical trials, waiver of FDA application fees, and market exclusivity for seven years following approval.
Early results from an ongoing Phase 1/2 clinical trial showed encouraging safety and efficacy data. The initial findings from the first three dose groups demonstrated that BEAM-302 was well tolerated and led to dose-dependent correction of the PiZ mutation. In the 60 mg dose group, total AAT protein levels exceeded the therapeutic threshold. The company has since begun dosing the fourth group with 75 mg and intends to present updated findings at a medical conference in the second half of 2025.
Beam also plans to begin dosing the first patient in Part B of the study, which will focus on AATD patients with mild to moderate liver disease, in the latter half of 2025. The investigational new drug (IND) application for BEAM-302 was cleared by the FDA in March 2025, and the treatment received Regenerative Medicine Advanced Therapy (RMAT) designation in May 2025.
BEAM-302 aims to provide a one-time A-to-G base correction of the PiZ mutation. This approach could reduce harmful protein build-up in the liver, increase levels of functional AAT protein, and help regulate inflammation—potentially addressing both liver and lung complications associated with AATD. Unlike current protein replacement therapies, this treatment could allow AAT levels to respond naturally to inflammation or infection. Based on current data, the correction is expected to offer long-lasting benefits.
Source: globenewswire.com
